The cost-effectiveness of natalizumab in patients with relapsing multiple sclerosis

被引：0
|
作者：
Meyer, K. [1 ]
Chiao, E. [1 ]
机构：
[1] Xcenda, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)68808-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A89 / A89
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF OFATUMUMAB VERSUS OCRELIZUMAB IN PATIENTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL
    Goncalves, N.
    Esparteiro, J.
    Machado, M.
    Ferreira, C.
    Guerreiro, T.
    VALUE IN HEALTH, 2022, 25 (12) : S78 - S78
  • [22] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Spelman, Timothy
    Herring, William L.
    Zhang, Yuanhui
    Tempest, Michael
    Pearson, Isobel
    Freudensprung, Ulrich
    Acosta, Carlos
    Dort, Thibaut
    Hyde, Robert
    Havrdova, Eva
    Horakova, Dana
    Trojano, Maria
    De Luca, Giovanna
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Grammond, Pierre
    Duquette, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Granella, Franco
    Lechner-Scott, Jeannette
    Sola, Patrizia
    Ferraro, Diana
    Grand'Maison, Francois
    Terzi, Murat
    Rozsa, Csilla
    Boz, Cavit
    Hupperts, Raymond
    Van Pesch, Vincent
    Oreja-Guevara, Celia
    van der Walt, Anneke
    Jokubaitis, Vilija G.
    Kalincik, Tomas
    Butzkueven, Helmut
    PHARMACOECONOMICS, 2022, 40 (03) : 323 - 339
  • [23] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Timothy Spelman
    William L. Herring
    Yuanhui Zhang
    Michael Tempest
    Isobel Pearson
    Ulrich Freudensprung
    Carlos Acosta
    Thibaut Dort
    Robert Hyde
    Eva Havrdova
    Dana Horakova
    Maria Trojano
    Giovanna De Luca
    Alessandra Lugaresi
    Guillermo Izquierdo
    Pierre Grammond
    Pierre Duquette
    Raed Alroughani
    Eugenio Pucci
    Franco Granella
    Jeannette Lechner-Scott
    Patrizia Sola
    Diana Ferraro
    Francois Grand’Maison
    Murat Terzi
    Csilla Rozsa
    Cavit Boz
    Raymond Hupperts
    Vincent Van Pesch
    Celia Oreja-Guevara
    Anneke van der Walt
    Vilija G. Jokubaitis
    Tomas Kalincik
    Helmut Butzkueven
    PharmacoEconomics, 2022, 40 : 323 - 339
  • [24] Natalizumab for relapsing multiple sclerosis
    Tenser, RB
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22): : 2387 - 2387
  • [25] Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence
    Graham, J. B.
    Earnshaw, S. R.
    Castelli-Haley, J.
    Oleen-Burkey, M.
    Johnson, K. P.
    VALUE IN HEALTH, 2007, 10 (06) : A381 - A381
  • [26] Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison
    Taheri, Saeed
    Sahraian, Mohammad Ali
    Yousefi, Nazila
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 71 - 84
  • [27] Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
    Hettle, Robert
    Harty, Gerard
    Wong, Schiffon L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) : 676 - 686
  • [28] Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy
    Mantovani, Lorenzo Giovanni
    Cortesi, Paolo Angelo
    Cardillo, Alessandra
    Santoni, Laura
    Prosperini, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 13 - 28
  • [29] COST-EFFECTIVENESS OF CLADRIBINE TABLETS IN THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL
    Pinheiro, B. A.
    Guerreiro, R.
    Costa, J.
    Silva Miguel, L.
    VALUE IN HEALTH, 2018, 21 : S339 - S339
  • [30] Clinical and radiological effectiveness of natalizumab extended dosage interval in patients with relapsing multiple sclerosis
    Garcia-Estevez, Daniel A.
    Perez-Lorenzo, Gema
    Jose Fernandez-Perez, M.
    Cid-Rodriguez, Carmen
    Ozaita-Arteche, Guillermo
    REVISTA DE NEUROLOGIA, 2022, 74 (08) : 265 - 268
12345